0A4W Stock Chart & Stats
$26.87
$0.00(0.00%)
At close: 4:00 PM EDT
$26.87
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$18.62 - $26.87
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$4.43B
Enterprise Value$3.49K
Total Cash (Recent Filing)$956.47M
Total Debt (Recent Filing)$73.85M
Price to Earnings (P/E)11.6
Beta0.11
Next Earnings
Nov 11, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.25
Shares Outstanding171,235,870
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$33.71Price Target Upside25.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.58
Revenue Forecast (FY)$1.24B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and materially higher equity provide durable financial flexibility to fund commercialization, pipeline programs and BD without near-term refinancing risk. This balance-sheet strength supports capital allocation optionality through 2–6 months and cushions execution hiccups.
Scaled, Profitable Commercial FranchiseRevenue scaled substantially from 2021 to TTM, and the company has moved to sustained profitability with robust net margins. A diversified revenue mix (NUPLAZID + DAYBUE) and growing prescriptions create a durable cash‑earning base to fund operations and R&D over the medium term.
Advancing Pipeline And Regulatory WinsCompleted Phase II enrollment and Fast Track for remlifanserin plus a positive CHMP for trofinetide represent structural product expansion potential. Successful readouts and EU approval would meaningfully broaden addressable markets and diversify revenues beyond the current U.S. franchise.
Bears Say
Cash-flow VariabilityFree cash flow generation is positive but less consistent: a recent ~31% step-down in FCF versus prior periods signals variability in cash conversion. That volatility can constrain discretionary investments or require conservatism in reinvestment and BD planning over the next several quarters.
High Gross-to-net AdjustmentsSustained gross‑to‑net at ~24% is a structural headwind to realized revenues and margins. High rebate/discount levels compress cash receipts relative to reported sales and magnify sensitivity of profitability to pricing and payer negotiations over the medium term.
Dependence On Binary Trial OutcomesMaterial growth expectations hinge on upcoming pivotal readouts and approvals. These binary clinical/regulatory outcomes create execution risk: unfavorable or inconclusive results would reduce future revenue diversification and could force cost or strategy changes lasting beyond a few quarters.
ACADIA Pharmaceuticals News
0A4W FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest share price was $18.62 and its highest was $26.87 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $4.43B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 96 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Aug 04, 2026. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.068 by $0.112.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.19.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 171,235,870 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.18 in its last earnings report, beating expectations of $0.068. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0A4W
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.71 (25.47% Upside)
$33.71 (25.47% Upside)
Blogger Sentiment
Bullish
GB:0A4W Sentiment 86%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.76%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
0A4W Company Deck
0A4W Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear near-term catalysts: robust Q2 results (total revenues +17%), pronounced DAYBUE STIX uptake (DAYBUE +30% YoY), healthy NUPLAZID growth (+10% YoY) with new prescriptions up 20%, a positive CHMP opinion for trofinetide in Europe, and significant pipeline progress (remlifanserin Phase II enrollment complete, Fast Track designation, top-line data expected Sep–Oct 2026). Offsetting factors include rising SG&A, sizable gross‑to‑net adjustments (~24%), a lowered R&D spend guidance due to a shifted BD milestone, reimbursement and pricing uncertainties in Europe, and dependency on upcoming pivotal readouts (creating execution/timing risk). Overall, the positives — strong sales, upgraded DAYBUE guidance, regulatory wins and a deepening pipeline with imminent binary catalysts — outweigh the operational and timing risks presented.View all GB:0A4W earnings summaries0A4W Stock 12 Month Forecast
Average Price Target
$33.71
▲(25.47% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
―